April 30 – May 3, 2014 • Gaborone, Botswana
Worldwide, 35 million people are living with HIV. About 25 million of those people live in sub-Saharan Africa. About 1.6 million people were newly infected with HIV in sub-Saharan Africa last year.
In 2011, the HPTN 052 study found that early antiretroviral therapy could reduce HIV transmission by 96% in serodiscordant couples. Since then, treatment as prevention (TasP) has become a major strategy in the global fight against AIDS. In June 2012, the World Health Organization wrote a comprehensive guideline for treatment as prevention, asserting that, “TasP needs to be considered as a key element of combination HIV prevention and as a major part of the solution to ending the HIV epidemic.”
Treatment as Prevention in Africa (TasP Africa) was the first workshop devoted exclusively to treatment as prevention in Africa. TasP Africa brought together researchers in infectious disease, health leaders, policy makers, and drug industry representatives to review TasP efforts already underway in Africa, to receive updates on current studies, to consider difficulties in creating, monitoring and maintaining TasP programs, and to establish a TasP research agenda specific to Africa.
TasP Africa is organized by the Harvard School of Public Health AIDS Initiative (HAI) and sponsored by the following: